Abstract

Most synthetic bone grafts are either hard and brittle ceramics or paste-like materials that differ in applicability from the gold standard autologous bone graft, which restricts their widespread use. Therefore, the aim of the study was to develop an elastic, highly porous and biodegradable β-tricalciumphosphate/poly(L-lactide-co-ε-caprolactone) (β-TCP/PLCL) composite for bone applications using supercritical CO\textsubscript{2} foaming. Ability to support osteogenic differentiation was tested in human adipose stem cell (hASC) culture for 21 d. Biocompatibility was evaluated for 24 weeks in a rabbit femur-defect model. Foamed composites had a high ceramic content (50 wt\%) and porosity (65-67 \%). After 50 \% compression, in an aqueous environment at 37 °C, tested samples returned to 95 \% of their original height. Hydrolytic degradation of β-TCP/PLCL composite, during the 24-week follow-up, was very similar to that of porous PLCL scaffold both \textit{in vitro} and \textit{in vivo}. Osteogenic differentiation of hASCs was demonstrated by alkaline phosphatase activity analysis, alizarin red staining, soluble collagen analysis, immunocytochemical staining and qRT-PCR. \textit{In vitro}, hASCs formed a pronounced mineralised collagen matrix. A rabbit femur defect model confirmed biocompatibility of the composite. According to histological Masson-Goldner’s trichrome staining and micro-computed tomography, β-TCP/PLCL composite did not elicit infection, formation of fibrous capsule or cysts. Finally, native bone tissue at 4 weeks was already able to grow on and in the β-TCP/PLCL composite. The elastic and highly porous β-TCP/PLCL composite is a promising bone substitute because it is osteoconductive and easy-to-use and mould intraoperatively.

Keywords: Bone substitute, composite, adipose stem cells, osteogenic differentiation, rabbit distal femur defect, β-tricalciumphosphate, poly(L-lactide-co-ε-caprolactone).

*Address for correspondence*: Sanna Pitkänen, BioMediTech, Faculty of Medicine and Health Technology, FI-33014 Tampere University, Tampere, Finland.
Telephone number: +358 401901789 Email: sanna.pitkanen@tuni.fi

Copyright policy: This article is distributed in accordance with Creative Commons Attribution Licence (http://creativecommons.org/licenses/by-sa/4.0/).
the gold standard, while allogenic bone and bone substitutes are also used. Important patient groups affected by problems concerning bone transplants are young children, who do not have enough bone tissue to be harvested, and elderly people, whose bone quality is weak. In addition, several problems are related to the use of autologous bone transplants, such as morbidity of the harvesting site, insufficiency and viability of the harvested bone and infection (Freeman and McNamara, 2017; Van der Stok et al., 2011). Furthermore, even though allograft bone may provide enough bone, transplanted tissue might be rejected; also, proteins and osteoinductive factors might be denaturated following sterilisation (Boyce et al., 1999). Moreover, when using allografts, disease transmission and infection are recurring problems, as 18 % of donated femoral heads have been shown to be affected by bacterial or fungal infections (Barbour and King, 2003; Boyce et al., 1999; Freeman and McNamara, 2017). Therefore, there is an evident and growing need for safe, synthetic bone transplants and tissue engineering strategies.

Even though various biomaterials have been proposed for bone replacement, the study and development of these structures have rarely proceeded to clinical applications (de Misquita et al., 2016). Before a bone substitute can become a clinically used product, its efficacy and safety has to be demonstrated both in vitro and in vivo as well as in a clinical trial. According to the regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, a product cannot receive a CE mark without clinically proven data (Web ref. 1). An ideal bone substitute should be osteoconductive or osteoinductive, biocompatible, biodegradable (Van der Stok et al., 2011) and highly porous, with a pore size larger than 250 µm to allow cell and tissue ingrowth (Mathieu et al., 2005; Turnbull et al., 2017; Zadpoor, 2015) and vascularisation (Rouwkema et al., 2008). Furthermore, the implant should not induce the formation of fibrotic tissue (Van der Stok et al., 2011) or infection. Cost-effective, large-scale manufacturing is also important when designing a new bone substitute for clinical use.

Ceramics, such as hydroxyapatite and other calcium phosphates, are highly compatible with bone tissue and, therefore, the most widely used synthetic bone substitute materials for treating large bone defects. Among calcium phosphates, β-tricalcium phosphate (β-TCP) induces significantly more bone in an ectopic site in vivo as compared to hydroxyapatite (Chatterjea et al., 2013; Yuan et al., 2010) and, therefore, β-TCP was chosen as the calcium phosphate phase of the composite. However, there has been conflicting results concerning the osteoinductive properties of β-TCP and speculation that they might vary according to the surface properties of the material (Bohner and Miron, 2019; Duan et al., 2018). Calcium phosphate materials are hard and brittle, making them difficult to shape intraoperatively and implant. Synthetic polymers such as polylactide, polyglycolide, poly-ε-caprolactone and their copolymers are biocompatible and support osteogenic differentiation of stem cells in vitro (Campana et al., 2014; Jeong et al., 2008; Temple et al., 2014; Wang et al., 2016). Poly(L-lactide-co-ε-caprolactone) (PLCL) is a copolymer of ε-lactide and ε-caprolactone with highly desirable characteristics as an implant material: elasticity, flexibility, high tensile strength, controllable degradation rate and good biocompatibility (Holmbom et al., 2005; Wang et al., 2016). PLCL scaffolds have been used in bone tissue engineering although, as PLCL is inert, hydrophobic and lacks biological recognition sites, the interaction with tissue and cells is not good enough either in vitro or in vivo (Jeong et al., 2008; Wang et al., 2016). By using supercritical CO₂ (scCO₂) processing, it was possible to create a homogenous, porous composite of the bioactive β-TCP and elastic PLCL. scCO₂ foaming was chosen as the processing technique as it is easy, cost-effective and non-toxic. Furthermore, the technique enables the production of polymeric structures with different pore sizes and total porosities. Briefly, CO₂ becomes a supercritical fluid above its critical temperature and pressure (31.10 °C, 73.9 bar), adapting characteristics between a liquid and a gas. Polymeric materials can be dissolved in scCO₂ and, as the pressure is decreased controllably, the CO₂ gas nucleation and expansion creates the wanted porous structure inside the polymeric material (Mathieu et al., 2005).

Multipotent human adipose stem cells (hASCs) are easily available. Furthermore, hASCs have been widely studied in the field of bone tissue engineering in vitro (Kyllönen et al., 2013a; Kyllönen et al., 2013b; Ojasvi et al., 2015; Tirkkonen et al., 2013; Vanhatupa et al., 2015) and in vivo (Jeon et al., 2008; Wilson et al., 2012). Therefore, hASCs are a relevant cell type for studying both the cytocompatibility of a potential bone substitute and the ability of a scaffold to support osteogenic differentiation in vitro.

The aim of the current study was to overcome the major limitations of previous bone-application-intended materials, to develop an elastic, highly porous, biodegradable and biocompatible β-TCP/PLCL composite for bone applications by using scCO₂ and to test its performance both in vitro and in vivo. Furthermore, the aim was to create a composite mimicking the mechanical properties of cartilaginous soft callus, which serves as the natural scaffold for bone regeneration during bone healing. For the first time, it was shown that scCO₂ processing of β-TCP/PLCL composite with a high ceramic content (50 wt%) could be used to produce scaffolds with porosity as high as 65–67 %. Furthermore, β-TCP granules were brought to the surface of the composites by a dynamic compression treatment. In vitro studies with hASCs demonstrated both cytocompatibility and osteogenic capacity of the scaffold. Furthermore, biocompatibility, osteoconductivity and bone tissue ingrowth were shown in vivo in a rabbit femur defect model.
Materials and Methods

Composite manufacturing and characterisation
Composites were manufactured by melt-mixing PLCL-polymer (70L/30CL; Purasorb PLC7015, Corbion Purac Biomaterials, Gorinchem, the Netherlands) with 50 wt% β-TCP, having a particle size range between 100 and 300 µm (Plasma Biotal Ltd., Buxton, UK). Composites were foamed using scCO\textsubscript{2}, as described in the granted patent (Web ref. 2), by using a Supercritical Carbon Dioxide Reactor System (SFE250, Waters Ltd., MA, USA). The residual lactide monomer content was measured by gas chromatography (DC8000, CE Instruments, Rodano, Italy) after post-melting. Foamed blocks were cut into discs for \textit{in vitro} studies [diameter (Ø) = 8 mm, height (h) = 3 mm] and into cylinders for \textit{in vivo} studies for cancellous bone (Ø = 3.2 mm, h = 10 mm) and intramuscular implantation (Ø = 4.0 mm, h = 10 mm). All samples were sterilised by γ-irradiation with a minimum dose of 25 kGy.

Prior to \textit{in vitro} and \textit{in vivo} studies, elastic scaffolds were treated by dynamically pre-compressing them repeatedly in an aqueous environment at 37 °C for a minimum of 20 cycles and compression level of at least 50 %. Composites were imaged by using a scanning electron microscope (SEM; Philips XL-30) and Xradia MicroXCT-400 X-ray imaging system with a voxel size of 5.6 µm (Carl Zeiss X-ray Microscopy Inc.) before and after the compression treatment. Porosities and pore sizes were calculated from micro-computed tomography (µCT) images with Fiji (Schindelin et al., 2012) using BoneJ (Doube et al., 2010) plugin. All the visualisations were conducted with Avizo 9.3.0 Software (Thermo Fisher Scientific).

Mechanical testing of composites
Mechanical testing was performed for both intact and pre-compressed samples (Ø = 8 mm, h = 3.5 ± 0.6 mm), as dry at room temperature (RT) and in an aqueous environment at 37 °C using the Instron Electropuls E1000 (High Wycombe, UK) by compressing unconfined samples 1 mm/min until a 50 % strain was reached. Used crosshead speed was adapted from the standard ISO 604. Elastic modulus was determined from linear section of the stress-strain curve, between 0 and 20 % strain.

Hydrolytic degradation of composites \textit{in vitro} and \textit{in vivo}
Hydrolytic degradation of the porous composites \textit{in vitro} was studied at 4, 12 and 24 weeks at 37 °C in Sörensen buffer solution (n = 6) and \textit{in vivo} as intramuscular implantation on underside of the supraspinatus muscle (n = 6 at 4 and 12 weeks; n = 1 at 24 weeks due to strong scaffold degradation). A porous PLCL (70/30) polymer scaffold was used as a reference. Degradation was monitored by size exclusion chromatography (SEC) utilising a Waters Associates system equipped with a Waters 717Plus Satellite autosampler, a Waters 510 HPLC solvent pump, two linear PL gel 5 µm columns connected in series and a Waters 2414 differential refractometer. The number-average molecular weight (M\textsubscript{n}), weight-average molecular weight (M\textsubscript{w}) and polydispersity of the samples were determined against polystyrene standards at RT. Chloroform was used as the eluent and was delivered at a flow rate of 1 mL/min. Samples were dissolved in chloroform at a polymer concentration of 13.5 ppm. The injection volume was 100 µL.

Isolation, characterisation and seeding of hASCs \textit{in vitro}
hASCs were isolated from adipose tissue samples obtained from three female donors (40 ± 11 years old) undergoing surgical procedures at the Department of Plastic Surgery, Tampere University Hospital after patients gave their consent. The study was conducted in accordance with the Ethics Committee of the Pirkkanaa Hospital District, Tampere (R15161).

Isolation of hASCs was conducted using a mechanical and enzymatic protocol as described previously (Lindroos et al., 2009). Isolated hASCs were expanded in basic medium (BM) consisting of Dulbecco’s modified Eagle’s medium: nutrient mixture F-12 (DMEM/F-12 1 : 1; Thermo Fischer Scientific), 5 % human serum (HS; BioWest, Nuaille, France), 1 % antibiotics (100 U/mL penicillin; 100 U/mL streptomycin; Lonza) and 1 % L-glutamine (GlutaMAX I; Thermo Fischer Scientific). hASCs were cultured at 37 °C in 5 % CO\textsubscript{2} and medium was changed twice a week. Cells were detached with TrypLE Select (Life Technologies). Experiments were carried out at passage 3.

To verify the mesenchymal origin of the cells, surface marker expression of hASCs at passage 1 was characterised by fluorescent-activated cell sorter (FACSAria; BD Biosciences) as described previously (Lindroos et al., 2009). Monoclonal antibodies against CD14-PE-Cy7, CD19-PE-Cy7, CD45RO-APC, CD73-PE, CD90-APC (BD Biosciences), CD34-APC, HLA-DR-PE (Immunotools, Friesoythe, Germany) and CD105-PE (R&D Systems) were used. The analysis was performed on 10,000 cells per sample and unstained hASC samples were used to compensate for the background autofluorescence levels. The expression of the surface markers CD73, CD90 and CD105 was positive, the expression of CD14, CD19, CD45 and human leukocyte antigen DR isotype (HLA-DR) was negative and that of CD34 was moderate (Table 1). The surface markers’ expression of hASCs confirmed the mesenchymal origin of the cells (Dominici et al., 2006).

Before cell seeding, sterile composites were pre-compressed in BM and incubated for 24 h in BM at 37 °C. hASCs were seeded in a 50 µL medium drop at a density of 510 cells/mm\textsuperscript{2} into the scaffolds. Cells were allowed to attach for 2-3 h before 500 µL of BM or osteogenic medium (OM) were added. OM consisted of BM with the addition of 250 µM ascorbic acid 2-phosphate (Sigma-Aldrich), 10 mM
Table 1. Surface marker expression of hASCs at passage 1. Positive > 98 %; negative < 2 %; moderate < 50 % > 2 %. SD: standard deviation.

<table>
<thead>
<tr>
<th>Surface marker</th>
<th>mean ± SD</th>
<th>expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD14</td>
<td>Serum lipopolysaccharide binding protein</td>
<td>0.6 ± 0.6</td>
</tr>
<tr>
<td>CD19</td>
<td>B lymphocyte-lineage differentiation antigen</td>
<td>0.4 ± 0.2</td>
</tr>
<tr>
<td>CD34</td>
<td>Sialomucin-like adhesion molecule</td>
<td>34.8 ± 32.2</td>
</tr>
<tr>
<td>CD45</td>
<td>Leukocyte common antigen</td>
<td>1.6 ± 0.3</td>
</tr>
<tr>
<td>CD73</td>
<td>Ecto-50-nucleotidase</td>
<td>98.2 ± 1.3</td>
</tr>
<tr>
<td>CD90</td>
<td>Thy-1 (T-cell surface glycoprotein)</td>
<td>99.8 ± 0.1</td>
</tr>
<tr>
<td>CD105</td>
<td>SH-2, endoglin</td>
<td>98.3 ± 1.2</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>Major histocompatibility class II antigens</td>
<td>0.6 ± 0.1</td>
</tr>
</tbody>
</table>

β-glycerophosphate (Sigma-Aldrich) and 5 nM dexamethasone (Sigma-Aldrich). As a 2-dimensional (2D) control for alizarin red staining, 500 cells were seeded in 1 mL of BM or OM in a 24-well plate (Nunc, Roskilde, Denmark).

Cell viability and proliferation

Cell viability was evaluated qualitatively by staining hASCs with fluorescent live/dead-staining probes (Molecular Probes) after 7, 14 and 21 d. hASCs were incubated for 45 min at RT with a mixture of 0.5 µM calcein acetoxyethyl ester (Molecular Probes) and 0.25 µM ethidium homodimer-1 (Molecular Probes). Images of living cells (green fluorescence) and dead cells (red fluorescence) were acquired using an Olympus IX51 phase contrast microscope with fluorescence optics and Olympus DP30BW camera (Olympus).

Cell number was analysed quantitatively after 7, 14 and 21 d by analysing the total amount of DNA by CyQUANT Cell Proliferation Assay Kit (Molecular Probes), according to manufacturer’s protocol, as reported previously (Kyllönen et al., 2013a). Samples were analysed after two freeze-thaw cycles and fluorescence was measured at 480/520 nm with a microplate reader (Victor 1420). A parallel 100 µL samples in a 96-well plate (Nunc) were analysed by CyQUANT Cell Proliferation Assay Kit (Molecular Probes), according to manufacturer’s protocol, as reported previously (Kyllönen et al., 2013a). Results were processed with ABI PRISM® 7300 Sequence Detection System-software (Applied Biosystems). Single-strand cDNA was synthesised from total RNA using the High-Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems). Data were normalised to the expression of the housekeeping gene human acidic ribosomal phosphoprotein large P0 (hRPLP0).

Analysis of osteogenic differentiation in vitro

Alkaline phosphatase (ALP) activity was determined after 7, 14 and 21 d, as described previously (Kyllönen et al., 2013a). ALP activity was determined from the same cell lysates as total DNA content. Absorbance was measured at 405 nm (Victor 1420).

Soluble total collagen was analysed at 7, 14 and 21 d by Soluble Collagen Assay Sircol™ (Biocolor, Carrickfergus, UK), as described previously (Tirkkonen et al., 2013). Briefly, collagen was dissolved for 2 h at 4 °C with 0.5 M acetic acid (Merck) containing 0.1 mg/mL pepsin (Sigma-Aldrich), while gently shaking. Thereafter, 100 µL samples were dried with 500 µL of Sircol™ Dye Reagent (Sirius red in picric acid; Biocolor) for 30 min at RT, while gently shaking. Then, samples were centrifuged for 10 min at 13,400 g and the dyed collagen pellets were washed with 750 µL of ice-cold Acid-Salt Wash Reagent (Biocolor). After another 10 min centrifugation at 13,400 g, the dye was diluted by adding 250 µL of Alkali Reagent (Biocolor) on top of the dyed collagen pellet. Intensity of the dye was measured from two parallel 100 µL samples in a 96-well plate (Nunc) using a microplate reader (Viktor 1420).

Mineralisation was studied by alizarin red S staining after 14 and 21 d, as described previously (Kyllönen et al., 2013a). In brief, paraformaldehyde (Sigma-Aldrich)-fixed cell-scaffold constructs were stained with filtered 2 % alizarin red S (pH 4.2; Sigma-Aldrich) and photographed after several washing steps. Dye was extracted with cetylpyridinium chloride (100 mM, Sigma-Aldrich) and its intensity was determined by measuring the absorbance at 540 nm (Victor 1420).

Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) analysis was used to compare the relative expression of osteogenic genes in different experimental groups. Total RNA was isolated from hASCs at 14 and 21 d using the NucleoSpin RNA II kit reagent (Macherey-Nagel) according to the manufacturer’s protocol. Single-strand cDNA was synthesised from total RNA using the High-Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems). Data were normalised to the expression of the housekeeping gene human acidic ribosomal phosphoprotein large P0 (hRPLP0). Primer sequences and accession numbers for RPLP0 and osteogenic genes RUNX2a, OSTERIX and DLX5 are listed in Table 2. The qRT-PCR mixture contained cDNA, primers and SYBR Green PCR Master Mix (Applied Biosystems). Reactions were conducted with ABI PRISM® 7300 Sequence Detection System as reported previously (Kyllönen et al., 2013a). Results were processed with ABI PRISM® 7300 Sequence Detection System-software (Applied Biosystems).

Osteogenic marker proteins collagen type I (COL-I) and osteocalcin (OCN) were detected with an indirect immunocytochemical staining method. At 7, 14 and...
Table 2. Primer sequences and accession numbers of genes analysed by qRT-PCR.

<table>
<thead>
<tr>
<th>Name</th>
<th>Full name</th>
<th>Accession number</th>
<th>Sequence</th>
<th>Product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>hRPLP0</td>
<td>Ribosomal protein, large, P0</td>
<td>NM_001002</td>
<td>Forward 5'-AAT CTC CAG GGG CAC CAT T-3'</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reverse 5'-CGC TGG CTC CCA CTT TGT-3'</td>
<td></td>
</tr>
<tr>
<td>hALP</td>
<td>Alkaline phosphatase</td>
<td>NM_000478.4</td>
<td>Forward 5'-CCC CCG TGG CAA CTC TAT CT-3'</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reverse 5'-GAT GGC AGT GAA GGG CCTT CT-3'</td>
<td></td>
</tr>
<tr>
<td>hRUNX2A</td>
<td>Runx2A, variant 1</td>
<td>NM_001024630.3</td>
<td>Forward 5'-CTT CAT TCG CCT CAC AAA CAA C-3'</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reverse 5'-TCC TCG AAG AGA AAG TTT GCA-3'</td>
<td></td>
</tr>
<tr>
<td>hOSX</td>
<td>Osterix</td>
<td>AF_477981</td>
<td>Forward 5'-TGA GCT GGA GCG TCA TGT G-3'</td>
<td>79</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reverse 5'-TGG GGT AAA GGG CTT GGA-3'</td>
<td></td>
</tr>
<tr>
<td>hDLX5</td>
<td>Distal-less homeobox 5</td>
<td>NM_005221.5</td>
<td>Forward 5'-ACC ATC CGT CTC AGG AAT CG-3'</td>
<td>75</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reverse 5'-CCC CCG TAG GGC TGT AGT AGT-3'</td>
<td></td>
</tr>
</tbody>
</table>

hASCs were fixed with 4 % paraformaldehyde (Sigma Aldrich) in Dulbecco’s phosphate-buffered saline (DPBS) with 0.05 % Triton-X 100 (Sigma Aldrich) for 10 min followed by washing steps. Cells were blocked in 1 % bovine serum albumin (BSA) in DPBS for 1 h at 4 °C. Primary antibodies mouse monoclonal anti-COL-I (dilution 1 : 2,000; Abcam) and mouse monoclonal anti-OCN (dilution 1 : 100; Abcam) were diluted in 1 % BSA and incubated overnight at 4 °C. As a negative control, 1 % BSA without primary antibody was used. After washing steps, secondary antibody donkey anti-mouse AlexaFluor 488 IgG (dilution 1 : 1,000; Invitrogen) diluted in 1 % BSA was added and incubated for 45 min at RT. Cells were washed repeatedly and treated with 0.1 % 4, 6-diamidino-2-phenylindole (DAPI) (Sigma Aldrich) in DPBS for 5 min at RT. Finally, cells were washed and imaged using an Olympus IX51 phase contrast microscope with fluorescence optics and Olympus DP30BW camera (Olympus). Images were edited with Adobe Photoshop version CS4.

Animal experiments

The Finnish Animal Experiment Board (ESAVI/5398/04.10.07/2014) approved the animal study and used protocols. 20 female New Zealand white rabbits were used.

Anaesthesia was induced by subcutaneous injection of ketamine (35 mg/kg, Ketador vet® 100 mg/mL, Richter Pharma, Wels, Austria) and medetomidine (0.3 mg/kg, Domitor® 1 mg/mL, OrionPharma, Espoo, Finland). Intravenous propofol boluses (2-5 mg/rabbit, Vetofol® 10 mg/mL, Norbrook Laboratories, Newry, Ireland), ketamine bolus (10 mg/kg) or mask anaesthesia with 1.5 % isoflurane (IsoFlo® vet 100%, Abbott Laboratories, Chicago, IL, USA) were used during the surgical procedure if needed. Intravenous trimethoprim/sulfamethoxazole (15 mg/kg, Duoprim® 200/40 mg/mL, Intervet International, Boxmeer, the Netherlands) was used as an antibiotic prophylaxis. Intravenous carprofen (4 mg/kg, Norocarp® 50 mg/mL, Norbrook Laboratories) and buprenorphine (0.03 mg/kg, Bupaq® 0.3 mg/mL, Richter Pharma) were used as a pain medication.

A 20 mm skin incision was made on the lateral aspect of the right femoral condyle and a 3.2 mm diameter and 10 mm deep drilling hole was made above the lateral collateral ligament. Composites were moistened and pre-compressed in blood collected from the drilling hole prior to implantation. The drilling hole was filled with 3.2 × 10 mm cylinder-shaped β-TCP/PLCL composite implant and periostem and skin were closed.

For the degradation study, a skin incision was made midline over the spine between the scapulae and two 4 × 10 mm β-TCP/PLCL composites were inserted through an applicator tube to the right supraspinatus muscle and two 4 × 10 mm polymer implants to the left supraspinatus muscle. Subcutaneous atipamezole (0.75 mg/kg, Antisedan® 5 mg/mL, OrionPharma) was used to reverse the sedative effect of the medetomidine after the procedure. For postoperative pain, subcutaneous buprenorphine (0.03 mg/kg) and carprofen (4 mg/kg) were used. Subcutaneous metoclopramide (0.2 mg/kg, Primperan® 5 mg/mL, Sanofi Oy, Espoo, Finland) was used to increase the intestinal motility. Rabbits were in a cage rest for 2 weeks after the surgery and, then, in a large-group housing area. They had access to hay and water ad libitum. One rabbit died during the procedure due to anaesthesia-related causes and one died 3 d after the operation as a result of a complication unrelated to the femoral defect.

The 18 rabbits were randomly divided in groups of 6 animals and euthanised 4, 12 and 24 weeks after the procedure. Subcutaneous injection of medetomidine (0.3 mg/kg) and ketamine (35 mg/kg) was followed by intracardial injection of pentobarbital (300 mg/rabbit, Mebunat® vet 60 mg/mL, Orion Pharma Oy, Espoo, Finland). The intramuscular implants were collected for further analysis.

μCT analysis (MicroXCT-400, Zeiss) was performed on all the harvested femoral condyles.
before histological preparation. Tube voltage of 120 kV and tube current of 83 µA were selected. From each sample, 1,600 projections were taken with a 13.4 µm voxel size. Exposure time was 4 s. Projections were reconstructed with the manufacturer’s XMReconstructor software. Image processing and analysis were done with Avizo Software (Thermo Fisher Scientific). Thereafter, the femoral condyles were fixed in 10 % buffered formalin solution followed by routine ascending ethanol series and methyl methacrylate embedding. A hard-tissue microtome (Leica, SM2500) was used to cut 5 µm-thick slice. Masson-Goldner’s Trichrome (MGT) staining was performed.

**Statistical analysis**

Statistical analysis was performed with SPSS version 23 (IBM) using a non-parametric test, due to the small

---

**Fig. 1. β-TCP/PLCL composite characteristics before and after pre-compression treatment.** (a) Representative SEM (scale bar: 200 µm; PLCL coloured violet; β-TCP coloured pink) and µCT (arrows indicate the granules released from under the polymer film; scale bar: 1,000 µm) images. (b) Compressive stress at 20 and 50 % strain when dry and 1 h, 7 or 14 d at 37 °C in aqueous environment. (c) Modulus when dry and 1 h, 7 or 14 d at 37 °C in aqueous environment. Statistical significances indicated as * **p ≤ 0.05 (n = 6).**
The effects of stress and strain \((n = 6)\) on intact and pre-compressed composites and of pre-compressing and incubation at 37 °C on modulus \((n = 6)\) of composites were compared using Mann-Whitney U-test with Bonferroni correction. Effects of BM or OM in combination with the composite on cell number, ALP activity, mineralisation, soluble collagen amount and gene expression were compared using Mann-Whitney U-test with Bonferroni correction. Results were considered significant when \(p < 0.05\). Experiments for cell number, ALP activity, mineralisation and soluble collagen amount were repeated with 3 donor lines each with 3 parallel samples \((n = 9)\). Experiments for gene expression were repeated with 3 donor lines each with 2 parallel samples \((n = 6)\).

Results

Characteristics of the composite

Scaffold porosity was 65-67 %, with an average pore size of 380 ± 130 μm. In addition, compressive stress at 20 and 50 % strain and modulus were analysed at different time points. SEM images (Fig. 1a) showed that before pre-compression treatment, β-TCP (coloured pink) was mainly on the cutting surface of the composite, while the surfaces of the pores were smooth and a PLCL film (coloured violet) mainly covered the β-TCP granules. However, the effect of the pre-compression was evident, as after the protocol the PLCL surface of the pores had ruptured and β-TCP granules protruded through it. Furthermore, SEM images demonstrated that the treatment tore additional holes in the pores of the composite. µCT images agreed with SEM images as they revealed that after the treatment more β-TCP granules were on display on the pore surfaces or even detached from the polymer phase in contrast to intact composite (Fig. 1a).

Both the compression treatment and warming at 37 °C had a significant effect on the mechanical properties of the composite. The compression treatment of a dry composite decreased the modulus significantly in contrast to an intact composite, but 1 h at 37 °C aqueous solution treatment erased such a difference (Fig. 1c). The same phenomenon was seen in the compressive stress analysis at both 20 and 50 % strain (Fig. 1b). Moreover, warming and wetting of the intact composite significantly decreased the modulus in comparison to dry intact composite (Fig. 1c). Intriguingly, both modulus and strength increased between 1 h and 7 d in an aqueous environment at 37 °C (Fig. 1b,c). No samples were broken during the compression analysis and samples tested in an aqueous environment at 37 °C returned to 95 % of their original height after the 50 % compression.

Hydrolytic degradation of the composite in vitro and in vivo

Molecular weight \(M_n\) and \(M_w\) change, caused by hydrolytic degradation of the polymer chains in

![Fig. 2. Hydrolytic degradation analysis results.](image)

- **a**: β-TCP/PLCL in vitro and in vivo
- **b**: PLCL in vitro and in vivo

\(M_n\) and \(M_w\) of (a) β-TCP/PLCL composites and (b) PLCL scaffolds were analysed in vitro and in vivo after 4, 12 and 24 weeks.
both β-TCP/PLCL composites (Fig. 2a) and PLCL polymer scaffolds (Fig. 2b), was analysed both in
vitro and in vivo. $M_n$ and $M_w$ of the samples were determined at 4, 12 and 24 weeks and the results
showed that the degradation in vitro was similar to that in vivo for both materials. Furthermore, scaffold
molecular weight had already decreased significantly during the first 4 weeks. In addition, $M_n$ and $M_w$
of the composite scaffold decreased by approximately 90% during the 24-week follow-up. The neat polymer
scaffold had initial $M_n$ and $M_w$ values higher than the composite but the difference in the degradation
profile was evened out in 4 weeks, after which no clear differences were seen between the materials or the
in vitro and in vivo environments. The residual L-lactide content after melt-extrusion and scCO$_2$-
foaming for the PLCL scaffold was 0.09 wt% and for the β-TCP/PLCL composite 0.06 wt%.

Viability and proliferation of hASCs in vitro
Cell viability was very good since only single
dispersed dead cells were observed in cultures. In
BM, cell number was clearly less than that in OM at
7 d (Fig. 3) and the difference was evident also at 14
and 21 d. Cell number was similar in OM at 7 d and
BM at 21 d.

Cell proliferation was analysed by fluorescent
CyQUANT proliferation assay after 7, 14 and 21 d in
culture. In concordance with the live/dead staining,
cell number was significantly larger in OM in contrast
to BM at all time points (Fig. 4a). Moreover, cell
number as indicated by live/dead staining was similar
in OM at 7 d and BM at 21 d. Variation among the
different donor cell lines was evident in proliferation
analysis, as OM did not increase the proliferation of
hASCs in comparison to BM from one of the donors
as it did for the other two.

Osteogenic differentiation of hASCs in vitro
ALP activity (Fig. 4b) was significantly greater in OM,
in contrast to BM at 7 and 14 d. Furthermore, ALP
activity in both BM and OM increased significantly
from 7 to 14 d. However, ALP activity did not rise
significantly from 14 to 21 d in either BM or OM. ALP
activity varied between different donor cell lines and
especially one donor cell line had higher ALP activity
in comparison to the others.

Total collagen amount did not vary notably among
BM and OM groups at 7, 14 or 21 d (Fig. 4c). Collagen
amount increased in both study groups slightly
from 7 to 14 d; however, collagen amount seemed to
decline from 14 to 21 d.

hASCs produced a pronounced mineralised
matrix on the composite in both BM and OM at
14 and 21 d (Fig. 4e). Furthermore, they produced
notably more mineralised matrix on the scaffold in
comparison to hASCs seeded on cell culture plastic
(2D) at 21 d (Fig. 4e). At 14 d there was no difference
between BM and OM. However, at 21 d, the mineral
amount in OM was significantly larger than that in
BM (Fig. 4d).

Immunocytochemical staining of COL-I was
conducted at 7, 14 and 21 d. In BM, COL-I expression
was modest at all time points (Fig. 5a). However, in
OM, a clear development of a collagenous matrix
was seen during the 3-week experiment: at 7 d,
cells were producing COL-I; at 14 d, cells were still
producing COL-I and had also excreted COL-I to the
extracellular matrix (ECM); at 21 d, there was a strong
extracellular COL-I matrix seen in the representative
image (Fig. 5a). In addition to COL-I, OCN was
also stained at 14 and 21 d. OCN was expressed in
both BM and OM at both time points; however, the
staining was slightly stronger in OM at both time
points (Fig. 5b).

Fig. 3. Viability of hASCs in β-TCP/PLCL composites. Representative images of live/dead stained hASCs
cultured in β-TCP/PLCL composites in BM or OM after 7, 14 and 21 d in culture. Scale bar: 500 µm.
qRT-PCR analysis for osteogenic genes \textit{ALP}, \textit{RUNX2a}, \textit{OSX} and \textit{DLX5} was conducted at 7, 14 and 21 d. Relative gene expression did not significantly differ in BM in comparison to OM during the experiment, although, the expression of \textit{RUNX2a} (\(p\) values between groups at 7 d: 0.394; 14 d: 0.078; 21 d: 0.310) and \textit{OSTERIX} (\(p\) values between groups at 7 d: 0.394; 14 d:0.123; 21 d: 0.240) was higher in OM as compared to BM at all time points (Fig. 6).

Bone regeneration within composites in rabbit femur defects

Bone was already able to grow on the surface as well as form inside the composite at 4 weeks (Fig. 7). The increased bone growth was observed on the surface and inside the composite at 12 and 24 weeks. In the 4-week \(\mu\)CT and histological staining images, some bone formation could be seen beyond the original bone margins, which was most likely a periosteum-induced reaction and not bone formation induced by the implant. Histological staining showed no signs of fibrous tissue or formation of cysts during the 24 weeks. \(\mu\)CT imaging confirmed the histological staining results. In addition, especially the representative \(\mu\)CT images at 24 weeks showed that the composite had degraded as compared to 4- and 12-week images (Fig. 7).

Discussion

Composites consisting of calcium phosphates and synthetic polymers have presented promising results in bone engineering applications and it has been
suggested that among biomaterials, composites are the most promising strategy for bone regeneration (de Misquita et al., 2016). ScCO$_2$ processing is a very interesting processing method for polymeric tissue engineering structures as it is totally non-toxic, cost effective and has low critical parameters ($T_c$: 304 K; $P_c$: 7.5 MPa) enabling the addition of biomolecules, such as bone morphogenetic protein 2 (BMP-2), into the structure during processing (Duarte et al., 2013). The study aim was to manufacture a composite with high β-TCP content, with porosity similar to that of human cancellous bone. In scCO$_2$ processing, the higher ceramic content decreases the porosity and increases the average pore size of the composite (Mathieu et al., 2006). Moreover, 5 wt% β-TCP content has been suggested to be the upper limit in order to obtain a homogenous and interconnected pore structure (Mathieu et al., 2006). In contrast to previous studies, it was possible, for the first time, to create a composite with 50 wt% β-TCP content with porosity as high as 65-67 % and average pore size of 380 µm by using scCO$_2$. Previously, Mathieu et al. (2006) manufactured polylactide (PLA)/β-TCP composites by scCO$_2$ with 74 % porosity but with only 10 % ceramic content. Moreover, Diaz-Gomez et al. (2017) reported PCL/fibroin/hydroxyapatite (70/20/10 %)
composites processed by using scCO$_2$ with average porosity of 69.7%.

Another challenge related to manufacturing polymer-ceramic composites by using scCO$_2$ is that the otherwise homogeneously distributed ceramic granules are covered by a polymer surface. To the authors’ knowledge, this was the first study overcoming this problem by using a dynamic compression treatment for the composites conducted in an aqueous environment at 37 °C. The treatment tore the polymer surface and β-TCP granules protruded on display as shown in the SEM images. The display of the β-TCP granules on the composite surface is highly important for the early interaction of the composite with cells and tissues, because PLCL lacks biological binding sites (Jeong et al., 2008; Wang et al., 2016) whereas β-TCP has the ability to bind to bone tissue (Barrere et al., 2006; Chatterjea et al., 2013) and induce osteogenic differentiation of mesenchymal stem cells (Marino et al., 2010). In addition, as the compression treatment tore additional holes in the PLCL pore surfaces, it increased the micro porosity and interconnectivity of the composites.

The modulus of the composite was more similar to the modulus of cartilage (2.4-10 MPa) (Beck et al., 2016) than to that of trabecular bone (10.75-13.66 GPa) (Peters et al., 2018), thus mimicking the soft callus formed during natural bone healing. Therefore, a bone defect treated with this composite would still require additional fixation to restrain the defect site. The closest comparable clinically approved composite material to the study composite is the bone void filler chronOS™ Strip from DePuy Synthes, which comprise PLCL and β-TCP granules. The compression strength of the β-TCP/PLCL composite analysed dry at RT was 1.1 MPa at 20 % strain and 3 MPa at 50 % strain. The compressive strength of the chronOS™ β-TCP granules is approximately 5 MPa (product manual of chronOS™), which is of the same order as the strength of the composite described in the current study. However, to the authors’ knowledge, the strength of the composite chronOS™ Strip has not been reported. Shikinami et al. (2006) compared different P(DL)LA-based composites and reported the compression strength of 5.4 MPa for a porous β-TCP/ P(DL)LA (weight ratio 70/30) analysed at RT. Moreover, Mathieu et al. (2006) reported the compression strength of approximately 3.5 MPa for a porous PDLA/β-TCP (weight ratio 90/10) composite also analysed dry at RT. As the requirements for an ideal bone substitute are highly demanding, the development of a scaffold may require compromising between achieving good cell and tissue response, desirable mechanical as well as user-friendly properties (Turnbull et al., 2017).

The compression treatment significantly decreased both modulus and strength at 20 and 50 % strain, when samples were tested dry at RT. However, the aqueous

![Fig. 6. Relative gene expression of osteogenic genes in hASCs in β-TCP/PLCL composites. (a) ALP, (b) RUNX2a, (c) OSTERIX and (d) DLX5. Results (n = 6) are expressed relative to hRPLP0 and 7 d BM result.](https://www.ecmjournal.org)
environment at 37 °C, simulating the physiological environment, diminished these differences. This is due to PLCL’s glass transition temperature, which is between 21 and 22 °C (Ahola et al., 2013). β-TCP particles were not able to reinforce the porous composite matrix because the polymer chains seemed to be mobile at 37 °C, making the composite highly elastic. During incubation at 37 °C, both intact and pre-compressed composites started to recover from the initial drop of modulus and strength, as there was a rise from 1 h to 7 d at 37 °C. van der Pol et al. (2010) proposed that increasing the amount of β-TCP over 5 wt% in a scCO\textsubscript{2}-processed composite would make the composite more brittle and make it lose its ability to sustain any deformation. However, present results contradicted this suggestion. The increase in modulus between 1 h and 7 d at 37 °C was likely to be related to the reorganisation of the polymer matrix, e.g. crystallisation or an aging type phenomenon in aqueous environment at 37 °C, enabling the polymer chains to organise towards energetically more stable conformations (Pan et al., 2007; Zong et al., 1999). However, within limits of the present study, the true mechanism could not be determined.

By monitoring the hydrolytic degradation both in vitro and in vivo, the aim was to define how accurately the in vitro degradation extrapolated to the situation in vivo. Because the degradation characteristics may depend e.g. on the polymer or the manufacturing method, the molecular degradation profile in vitro may model relatively accurately the degradation in vivo (Weir et al., 2004) or differ significantly (Koepp et al., 2004). The results showed that the hydrolytic degradation of the scCO\textsubscript{2}-foamed β-TCP/PLCL composite and the following degradation-dependent structural changes could be studied with very good accuracy in the in vitro model. The small differences in the degradation rate during the first 4 weeks could be related to the β-TCP content, which slows down the hydrolytic degradation by neutralising the acidic degradation products of lactide-based polymers (Niemelä, 2005). Previously, the same polymer and composite with β-TCP content were studied in vitro as non-foamed blocks (Ahola et al., 2013). Despite the different initial molecular weight but similar residual monomer content, the molecular weight was similar after 12 weeks of incubation at 37 °C (Ahola et al., 2013) to that of the present foamed scaffolds.

Results showed that the composites were cytocompatible in vitro, as hASC viability was very high, with only some dead cells, as observed by live/dead staining. Both live/dead staining and cell proliferation analysis showed that hASCs proliferated more when cultured in OM as compared to BM, as expected according to previous results with hASCs (Kyllönen et al., 2013a; Tirkkonen et al., 2013; Vanhatupa et al., 2015).

Osteogenic differentiation of hASCs in composites was demonstrated by using various methods. Induction of ALP activity clearly occurred in BM and OM, even though the level of ALP activity was significantly higher in OM than in BM at 7 and 14 d. ALP activity as well as ALP expression peaked at 14 d, as ALP expression is related to the matrix maturation phase of bone ECM development (Lian et al., 2012). Moreover, total soluble collagen amount was generally very similar in both BM and OM. Collagen amount was only slightly larger in OM at 7 and 21 d as compared to BM. The slight decrease in soluble collagen from 14 to 21 d might be due to the development of osteogenic ECM. Mineralised collagen fibrils are the elementary building blocks.

Fig. 7. Bone formation in rabbit femora. Representative images of MGT-stained histological samples (scale bar 1 mm) from rabbit femora with implanted composites and corresponding µCT imaging (scale bar 2 mm) 4, 12 and 24 weeks after implantation. * indicating periosteum-induced bone formation.
of bone (Nair et al., 2013) and the mineralisation of collagen fibrils may affect the solubility of collagen during soluble collagen analysis. Moreover, dense COL-I matrix promotes the osteogenic differentiation of mesenchymal stem cells attaching to it (Buxton et al., 2008). As alizarin red staining already confirmed the formation of a strong mineralised matrix in both BM and OM at 14 d and the immunocytochemical staining of COL-I was especially strong in OM at 14 and 21 d, it is possible that mineralised collagen matrix, typical of bone development, had developed in cell cultures. In addition, the detection of the late osteogenic marker OCN by immunocytochemical staining confirmed the late osteogenic differentiation of hASCs in the composites (Lian et al., 2012). The expression of osteogenic genes was in line with the literature concerning bone development, as ALP and RUNX2a expression peaks are related to the early phase of differentiation whereas OSTERIX expression peaks to the late phase of differentiation (Lian et al., 2012). Moreover, when comparing the formed mineralised matrix on the scaffold in BM to that on the 2D control in BM, the composite itself seemed to induce osteogenic differentiation of hASCs even without the addition of osteogenic supplements.

Bone regeneration within composites implanted in a rabbit distal femur defect model was demonstrated in a 24-week study. During implantation, the composite proved to be easy to handle and implant due to its elasticity and ability to recover after compression. Poly(L-lactide) implants (Pihlajamäki et al., 2006) and composites (van der Pol et al., 2010) have been shown to induce an inflammatory reaction due to acidic degradation products leading to the development of a fibrous capsule around the implant. However, the femur defect model demonstrated that the biocompatibility of the β-TCP/PLCL composite was good, as no formation of fibrous layer, cysts or infection was detected in any of the animals during the 24-week study. Moreover, the composite was shown to be osteoconductive as, according to the MGT staining and μCT images, bone was already able to grow on the surface of the composite and infiltrate inside the porous structure at 4 weeks. In contrast to the present results, van der Pol et al. (2010) showed that a PLA/β-TCP (95/5 wt%) composite manufactured by scCO₂ processing induces the formation of a clear fibrous layer between the implant and mineralised tissue at 8 and 16 weeks in sheep femur defects. In concordance with the present results, Pihlman et al. (2018) studied the same porous β-TCP/PLCL composites and demonstrated the osteoconductivity and ingrowth of bone and vascular tissue in a rabbit calvarial defect model. Moreover, the β-TCP/PLCL composite gives structural support and blocks the surrounding soft tissues from bulging into the defect (Pihlman et al., 2018). Also, Pihlman et al. (2018), in their in vivo study, concluded that the mouldable and resilient composite is easier to use in clinics in contrast to most available products used for bone substitutes.

Conclusions

A highly porous, biodegradable, elastic and easy-to-handle β-TCP/PLCL composite to serve as a bone substitute was created. To the authors’ knowledge, the present study was the first one reporting a composite manufactured by scCO₂, processing with a high ceramic content (50 wt%) and porosity as high as 65-67 %. Furthermore, β-TCP particles in the processed composites were uncovered by using a dynamic compression treatment.

The β-TCP/PLCL composite was cytocompatible and supported osteogenic differentiation of hASCs in vitro. The formation of a collagenous mineralised matrix already after 3 weeks in vitro was an especially clear indication of the composite’s potential as a bone substitute. Furthermore, the rabbit femur defect model showed that the β-TCP/PLCL composite was biocompatible, as it did not elicit the formation of fibrous capsule, cysts or infection. Finally, the β-TCP/PLCL composite was osteoconductive, as bone tissue was already able to grow on the surface and inside the scaffold at 4 weeks. To conclude, the β-TCP/PLCL composite foamed by using scCO₂ is a very promising bone substitute material and a potential candidate for use in clinics.

Acknowledgements

The work was financially supported by the Finnish Funding Agency for Innovation, a grant from The Finnish Cultural Foundation, Doctoral program of Faculty of Medicine and Life Sciences (University of Tampere) and the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital. Authors would like to thank MSc Sanna Karjalainen from Biomaterials and Tissue Engineering Group (BioMediTech, Faculty of Medicine and Health Technology, Tampere University) for her contribution to in vitro experiments concerning composite manufacturing and testing and BioCiteHisto Oy (Tampere, Finland) for their expertise in histological samples and stainings. In addition, the authors would like to acknowledge the assistance and excellent equipment of Tampere Imaging Facility (BioMediTech, Faculty of Medicine and Health Technology, Tampere University) and Ms Anna-Maija Honkala, Ms Miaa Juntunen and Mrs Sari Kalliokoski for their excellent technical assistance in stem cell isolation and culture.

Authors declare no competing interests.

References


Much attention has been paid to bone-forming cells in 3D culture. Eur Cell Mater 27: 932-937.


substitutes. However, existing composite scaffolds with the porosity needed for osteoconduction do not approach the modulus required to replace lost bone function and avoid the need for bone fixation – particularly for lower extremity defects. If immediate restoration of bone mechanical properties is not a design goal, what factors determine the strength needed of candidate scaffolds for bone repair? Would this differ for grafts used in maxillofacial versus long bone defects?

**Authors:** The main aims in composite development are optimal porosity, biocompatibility and osteoconductivity. In addition, easy intra-operative tailoring is highly important, as, for instance, ceramics are not easy to handle or tailor during a surgery, which hinders surgeons’ work. With that said, future efforts aim to improve composite mechanical properties to create a composite with similar modulus to subchondral spongiosa. The requirements for mechanical strength of the scaffold are, of course, lower in maxillofacial defects in comparison to long bone defects and, therefore, the composite described in the study is suitable for non-load bearing sites.

**Ryan Porter:** Supercritical CO$_2$ has also been used for biomaterial sterilisation processes, including bone allografts. Was the γ-irradiation step included for precautionary measures? Would both steps be required in a good manufacturing practice (GMP) manufacturing protocol for the proposed composite?

**Authors:** It is true that the processing method can also be used as a sterilisation method. γ-irradiation sterilisation was used for precautionary measures and because it is the commonly used and highly trusted sterilisation method among clinical products. The composite is classified as a medical device and, therefore, there is no need for a GMP-level manufacturing protocol but an ISO13485 manufacturing protocol is sufficient.

**Ryan Porter:** What might be the challenges to clinically translate bone graft alternatives manufactured using supercritical CO$_2$?

**Authors:** These are highly important matters when developing a clinical product. The challenges in clinical translation of scCO$_2$-processed structures are related to producing a homogenous pore structure in a reproducible manner. Furthermore, the scalability of the processing is another challenge to overcome in case of a large-scale production.

**Pamela Habibovic:** A problem of the in vitro experiments is the (partially strong) osteogenic differentiation in BM samples. This could indicate pre-differentiation of the used cells, pointing towards an activation of differentiation by the material itself or problems in the assays. This could be clarified by including data of suitable control groups in the results section, e.g. cells cultured in BM and OM on tissue culture plastic etc.

**Authors:** The reason for not using a 2D well plate control was the challenge related to the differences between experimental setups in 3D and 2D. Due to these differences, e.g. notable differences in cell seeding density and cell attachment, the results between the two setups would not be fully comparable.

**Editor’s note:** The Scientific Editor responsible for this paper was Joost de Bruijn.